LYRA
Lyra Therapeutics, Inc.
Key Financials
Net Income
$-28919000
↑ 69.0%
Revenue
$398000
↓ 74.1%
Total Assets
$36.1M
↓ 45.6%
Operating Income
$-31022000
↑ 67.8%
EPS (Diluted)
$-18.62
↓ 1202.1%
Shareholders' Equity
$-10717000.00
↓ 192.4%
Total Liabilities
$46.8M
↓ 14.5%
Operating Cash Flow
$-28859000.00
↑ 58.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/15/2026 | View on SEC |
| 15-12G | 4/30/2026 | View on SEC |
| 25 | 4/20/2026 | View on SEC |
| 8-K | 4/17/2026 | View on SEC |
| 8-K | 4/10/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
| 10-K | 3/31/2026 | View on SEC |
| EFFECT | 3/26/2026 | View on SEC |
| EFFECT | 3/26/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LYRA |
| Company Name | Lyra Therapeutics, Inc. |
| CIK | 1327273 |
| Sector | Surgical & Medical Instruments & Apparatus |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 3841 |
| SIC Description | Surgical & Medical Instruments & Apparatus |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-373-4600 |